https://www.mattheneus.com/ weekly 1.0 https://www.mattheneus.com/editorial daily 0.9 https://www.mattheneus.com/hta-intelligence weekly 0.85 https://www.mattheneus.com/evidence-methodology weekly 0.85 https://www.mattheneus.com/regulatory-strategy weekly 0.85 https://www.mattheneus.com/editorial/nice-national-healthtech-access-programme-rollout-2026-02 2026-02-19 monthly 0.8 https://www.mattheneus.com/editorial/mhra-ce-marked-devices-indefinite-recognition-consultation-2026-02-20 2026-02-20 monthly 0.8 https://www.mattheneus.com/editorial/mhra-nice-integrated-scientific-advice-service-update-2026-02-20 2026-02-20 monthly 0.8 https://www.mattheneus.com/editorial/mhra-clinical-investigations-record-growth-neurotech-ai-2026-02-20 2026-02-20 monthly 0.8 https://www.mattheneus.com/editorial/eu-hta-jca-2026-evidence-readiness-playbook 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/nice-10-year-plan-access-implementation-signals-2026-02-21 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/nice-type-2-diabetes-sglt2-early-use-guidance-2026-02-18 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/ema-kygevvi-first-treatment-tk2-deficiency-2026-01-30 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/hta-evidence-limitations-section-operational-checklist-2026-02-21-v2 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/germany-hta-evidence-transferability-playbook-2026-02-21 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/pbac-committee-cycle-evidence-readiness-playbook-2026-02-21 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/europe-hta-comparative-evidence-transparency-priority-2026-02-21 2026-02-21 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-irm-2026-ai-evidence-retrieval-agenda-2026-01 2026-02-22 monthly 0.8 https://www.mattheneus.com/editorial/eu-comparative-evidence-assumption-traceability-2026-02-21 2026-02-22 monthly 0.8 https://www.mattheneus.com/editorial/ema-kygevvi-positive-opinion-tk2d-2026-02-22 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/ema-zynyz-anal-cancer-extension-opinion-evidence-2026-02-23 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/ema-fylrevy-positive-opinion-menopause-vms-evidence-2026-02-23 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/ema-kayshild-conditional-opinion-mash-f2-f3-2026-02-23 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/fda-bysanti-approval-bipolar-schizophrenia-evidence-planning-2026-02-20 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/fda-pitolisant-cataplexy-pediatric-narcolepsy-evidence-update-2026-02-17 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/ec-anktiva-bcg-nmibc-cis-conditional-authorization-2026-02-18 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/mhra-brensocatib-licensed-ncfb-bronchiectasis-evidence-2026-02-23 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/eu-biosimilars-evidence-operations-playbook-2026-02-23 2026-02-23 monthly 0.8 https://www.mattheneus.com/editorial/eu-scheer-risk-mandates-evidence-planning-playbook-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/ema-kygevvi-tk2-deficiency-positive-opinion-evidence-lineage-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/mhra-zanidatamab-ziihera-biliary-tract-cancer-single-arm-lineage-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/regulatory-operations-signals-evidence-timeline-risk-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/nice-ruxolitinib-vitiligo-rapid-review-final-draft-guidance-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/ema-rezurock-cgvhd-positive-opinion-reexamination-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/ema-kygevvi-positive-opinion-tk2d-evidence-lineage-2026-01-29 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/nice-osteoporosis-mta-scope-evidence-architecture-playbook-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/nice-cardiomems-final-guidance-heart-failure-remote-monitoring-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/ema-platform-approaches-evidence-planning-playbook-2026-02-24 2026-02-24 monthly 0.8 https://www.mattheneus.com/editorial/ema-eudravigilance-evidence-operations-playbook-2026-02-25 2026-02-25 monthly 0.8 https://www.mattheneus.com/editorial/ema-kygevvi-positive-opinion-rare-tk2d-evidence-lineage-2026-02-25 2026-02-25 monthly 0.8 https://www.mattheneus.com/editorial/nice-ng28-ta-refresh-consultation-evidence-governance-playbook-2026-02-25 2026-02-25 monthly 0.8 https://www.mattheneus.com/editorial/ema-levamisole-article31-prac-withdrawal-recommendation-2026-02-25 2026-02-25 monthly 0.8 https://www.mattheneus.com/editorial/ema-zynyz-chmp-opinion-scac-first-line-2026-02-25 2026-02-25 monthly 0.8 https://www.mattheneus.com/editorial/nice-dual-track-appraisal-evidence-governance-playbook-2026-02-25 2026-02-25 monthly 0.8 https://www.mattheneus.com/editorial/ema-rezurock-conditional-authorisation-cgvhd-reexamination-2026-02-25 2026-02-25 monthly 0.8 https://www.mattheneus.com/editorial/eu-evidence-financing-fee-governance-playbook-2026-02-26 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/ema-zynyz-scac-chmp-opinion-evidence-lineage-2026-02-26 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/nice-pegzilarginase-arg1-final-draft-guidance-2026-02-26 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/regulatory-lifecycle-quality-governance-playbook-2026-02-26 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/ema-tavneos-referral-advocate-data-integrity-review-2026-02-26 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/ema-zynyz-scac-indication-extension-opinion-2026-01-30 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/ema-mssg-stakeholder-framework-evidence-continuity-playbook-2026-02-26 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-lisocabtagene-maraleucel-follicular-lymphoma-added-benefit-not-proven-2025-07-15 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/cochrane-ai-platform-study-evidence-synthesis-governance-playbook-2026-02-19 2026-02-26 monthly 0.8 https://www.mattheneus.com/editorial/patient-preference-evidence-risk-calibration-playbook-2026-02-27 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/mhra-inluriyo-esr1-breast-cancer-approval-evidence-lineage-2026-02-27 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/nice-rare-disease-quality-standard-evidence-governance-playbook-2026-02-27 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/mhra-isotretinoin-prescribing-update-risk-minimisation-implementation-2026-02-27 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/ema-mcombriax-positive-opinion-combined-covid-19-influenza-vaccine-2026-02-27 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/unanchored-maic-target-population-governance-playbook-2026-02-27 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/ema-xolremdi-whim-positive-opinion-exceptional-circumstances-2026-02-26 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/nice-migraine-uptake-telemetry-evidence-feedback-loop-2026-02-27 2026-02-27 monthly 0.8 https://www.mattheneus.com/editorial/rwe-harmonization-cross-jurisdiction-evidence-governance-playbook-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/mhra-gcp-national-assessment-evidence-readiness-playbook-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/pbac-semaglutide-ecvd-obesity-pbs-recommendation-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/bayesian-itc-economic-modeling-oncology-price-negotiation-playbook-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/ema-acoziborole-eu-m4all-positive-opinion-single-arm-lineage-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/nice-bevacizumab-biosimilar-mcrc-guidance-direct-trial-lineage-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/pbac-tucatinib-her2-positive-metastatic-breast-cancer-pbs-recommendation-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/rare-disease-hta-access-evidence-architecture-china-global-playbook-2026-02-28 2026-02-28 monthly 0.8 https://www.mattheneus.com/editorial/pubmed-weekly-itc-publication-burst-evidence-governance-playbook-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/smc-donanemab-kisunla-resubmission-non-recommendation-early-alzheimers-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/idh1-aml-maic-covariate-audit-trail-playbook-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/ema-iloperidone-vanda-refusal-schizophrenia-bipolar-lineage-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/smc-sotatercept-winrevair-pah-non-recommendation-stellar-lineage-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/mhra-reclassification-evidence-package-right-first-time-playbook-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/smc-zuranolone-zurzuvae-non-recommendation-postnatal-depression-lineage-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/eu-reference-networks-2026-rare-disease-evidence-transfer-playbook-2026-03-02 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/pbac-belantamab-mafodotin-blenrep-rrmm-non-recommendation-lineage-2026-03-02 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/eu-hta-pbac-digital-submission-readiness-operating-model-2026-03-02 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/mhra-ixchiq-restrictions-chm-safety-review-global-adverse-events-2026-03-02 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/nma-rank-clustering-decision-confidence-playbook-2026-03-02 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/smc-marstacimab-hympavzi-restricted-acceptance-haemophilia-prophylaxis-2026-01-19 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/ema-palsonify-positive-opinion-acromegaly-pathfndr-trial-lineage-2026-03-02 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/nice-talazoparib-enzalutamide-ta1130-metastatic-prostate-cancer-2026-03-02 2026-03-02 monthly 0.8 https://www.mattheneus.com/editorial/ema-chmp-february-2026-portfolio-signals-evidence-planning-playbook-2026-03-03 2026-03-03 monthly 0.8 https://www.mattheneus.com/editorial/smc-exagamglogene-autotemcel-casgevy-accepted-sickle-cell-disease-2026-01-19 2026-03-03 monthly 0.8 https://www.mattheneus.com/editorial/ema-rhapsido-positive-opinion-chronic-spontaneous-urticaria-2026-02-26 2026-03-03 monthly 0.8 https://www.mattheneus.com/editorial/bayesian-nma-time-window-effect-modifier-governance-playbook-2026-03-03 2026-03-03 monthly 0.8 https://www.mattheneus.com/editorial/smc-nivolumab-ipilimumab-smc2820-msi-h-mcrc-acceptance-2026-03-03 2026-03-03 monthly 0.8 https://www.mattheneus.com/editorial/pbac-dapagliflozin-ckd-restriction-expansion-optimise-ckd-evidence-2025-12-24 2026-03-03 monthly 0.8 https://www.mattheneus.com/editorial/eu-jca-pico-disparity-legal-risk-evidence-operations-playbook-2026-03-03 2026-03-03 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-forum-berlin-science-policy-evidence-translation-playbook-2026-03-04 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/pbac-osimertinib-combination-egfrm-nsclc-positive-recommendation-2025-09 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/nice-durvalumab-muscle-invasive-bladder-cancer-ta1138-recommendation-2026-03-02 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/smc-serplulimab-hetronifly-non-recommendation-es-sclc-evidence-lineage-2026-03-04 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/nice-obinutuzumab-mmf-lupus-nephritis-ta1131-recommendation-2026-03-04 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/cross-modality-nma-taxonomy-governance-playbook-2026-03-04 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/smc-zolbetuximab-vyloy-acceptance-cldn182-her2-negative-gastric-gej-2026-03-04 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-biologics-pharmacy-substitution-evidence-governance-playbook-2026-03-04 2026-03-04 monthly 0.8 https://www.mattheneus.com/editorial/digital-delivery-itc-protocol-governance-playbook-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/nice-ta1134-dupilumab-severe-crsnp-recommendation-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/mhra-space-manufactured-pharma-evidence-readiness-playbook-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/nice-belantamab-mafodotin-ta1133-second-line-myeloma-recommendation-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-asciminib-cml-benefit-assessment-publication-iqwig-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/pbac-vorasidenib-idh-mutant-glioma-non-recommendation-icer-uncertainty-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/eu-act-eu-public-health-emergency-clinical-trial-guidance-evidence-planning-playbook-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-lecanemab-early-alzheimers-no-added-benefit-amnog-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/mhra-falsified-mounjaro-kwikpen-15mg-patient-safety-alert-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/frequentist-bayesian-nma-bridge-evidence-submission-governance-playbook-2026-03-05 2026-03-05 monthly 0.8 https://www.mattheneus.com/editorial/ai-mini-hta-medical-device-assessment-validation-governance-playbook-2026-03-06 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/nice-dupilumab-uncontrolled-copd-raised-eosinophils-final-draft-guidance-2026-01-26 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-resmetirom-mash-added-benefit-not-proven-evidence-unsuitable-2026-03-05 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-patient-reported-endpoint-completeness-evidence-governance-playbook-2026-03-06 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/nice-molnupiravir-covid19-review-sotrovimab-removal-evidence-lineage-2026-03-06 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/nice-ta878-covid19-update-sotrovimab-removal-2026-03-06 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/cochrane-openevidence-clinical-ai-evidence-governance-playbook-2026-03-06 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/mhra-rwe-scientific-dialogue-post-pilot-evidence-planning-playbook-2026-03-06 2026-03-06 monthly 0.8 https://www.mattheneus.com/editorial/mhra-phase-i-accreditation-scientific-advice-evidence-readiness-playbook-2026-03-07 2026-03-07 monthly 0.8 https://www.mattheneus.com/editorial/mhra-nirogacestat-desmoid-tumours-approval-defi-trial-lineage-2026-03-07 2026-03-07 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-donanemab-a25-134-added-benefit-not-proven-aaci-lineage-2026-03-07 2026-03-07 monthly 0.8 https://www.mattheneus.com/editorial/pbac-november-2025-psd-release-evidence-synthesis-readiness-playbook-2026-03-08 2026-03-08 monthly 0.8 https://www.mattheneus.com/editorial/ema-ojemda-conditional-opinion-paediatric-lgg-braf-lineage-2026-03-08 2026-03-08 monthly 0.8 https://www.mattheneus.com/editorial/nice-natalizumab-highly-active-rrms-post-dmt-recommendation-ta1126-2026-03-08 2026-03-08 monthly 0.8 https://www.mattheneus.com/editorial/pbac-omaveloxolone-friedreich-ataxia-recommendation-price-condition-2026-03-08 2026-03-08 monthly 0.8 https://www.mattheneus.com/editorial/uk-medtech-exceptional-use-to-fsn-evidence-operations-playbook-2026-03-08 2026-03-08 monthly 0.8 https://www.mattheneus.com/editorial/pbac-efgartigimod-alfa-subcutaneous-gmg-recommendation-2026-03-08 2026-03-08 monthly 0.8 https://www.mattheneus.com/editorial/interactive-nma-transparency-ipd-aggregation-evidence-governance-playbook-2026-03-08 2026-03-08 monthly 0.8 https://www.mattheneus.com/editorial/switzerland-hta-system-gap-analysis-evidence-operations-playbook-2026-03-09 2026-03-09 monthly 0.8 https://www.mattheneus.com/editorial/pbac-fedratinib-myelofibrosis-pbs-recommendation-itc-maic-nma-lineage-2026-03-09 2026-03-09 monthly 0.8 https://www.mattheneus.com/editorial/component-nma-intervention-decomposition-governance-playbook-2026-03-09 2026-03-09 monthly 0.8 https://www.mattheneus.com/editorial/ncpe-sotatercept-winrevair-hta-24041-non-reimbursement-pah-2026-03-09 2026-03-09 monthly 0.8 https://www.mattheneus.com/editorial/digital-health-hta-framework-convergence-evidence-operations-playbook-2026-03-09 2026-03-09 monthly 0.8 https://www.mattheneus.com/editorial/living-guideline-update-alert-nma-version-control-playbook-2026-03-10 2026-03-10 monthly 0.8 https://www.mattheneus.com/editorial/smc-zilucoplan-gmg-non-recommendation-economic-evidence-gap-2026-03-10 2026-03-10 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-pembrolizumab-head-neck-neoadjuvant-adjuvant-minor-added-benefit-hint-2026-03-10 2026-03-10 monthly 0.8 https://www.mattheneus.com/editorial/pbac-tezepelumab-severe-uncontrolled-asthma-dual-pathway-listing-lineage-2026-03-10 2026-03-10 monthly 0.8 https://www.mattheneus.com/editorial/pbac-durvalumab-perioperative-mibc-recommendation-evidence-uncertainty-2026-03-10 2026-03-10 monthly 0.8 https://www.mattheneus.com/editorial/ema-daybu-trofinetide-refusal-rett-syndrome-clinical-meaningfulness-2026-03-10 2026-03-10 monthly 0.8 https://www.mattheneus.com/editorial/nice-epcoritamab-ta1139-relapsed-refractory-follicular-lymphoma-recommendation-2026-03-11 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/nma-acceptability-endpoint-governance-protocol-to-dossier-playbook-2026-03-11 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/nice-canagliflozin-ta1137-terminated-appraisal-no-evidence-submission-2026-03-11 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-resmetirom-mash-f2-f3-final-resolution-no-added-benefit-2026-03-05 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/ai-mdt-concordance-treatment-heterogeneity-evidence-governance-playbook-2026-03-11 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/nice-baloxavir-marboxil-ta1135-terminated-appraisal-no-evidence-submission-2026-03-11 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/smc-omaveloxolone-skyclarys-non-recommendation-friedreich-ataxia-economic-uncertainty-2026-03-11 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/itc-nma-interpretation-layer-cross-endpoint-governance-playbook-2026-03-11 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/mhra-clinical-trial-approval-2026-transition-evidence-operations-playbook-2026-03-12 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/zin-lecanemab-leqembi-non-reimbursement-advice-early-alzheimer-2026-02-13 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/who-ml4-medtech-regulation-evidence-governance-playbook-2026-03-12 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-avacopan-addendum-remission-week-26-no-added-benefit-2026-03-05 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/mhra-deuruxolitinib-leqselvi-approval-severe-alopecia-areata-2026-03-12 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/mhra-cprd-global-evidence-library-rwe-submission-readiness-playbook-2026-03-12 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-inavolisib-hr-positive-her2-negative-breast-cancer-amnog-resolution-2026-02-19 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/ai-reporting-lineage-controls-hta-evidence-readiness-playbook-2026-03-12 2026-03-12 monthly 0.8 https://www.mattheneus.com/editorial/rwe-endpoint-taxonomy-reimbursement-readiness-playbook-2026-03-13 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-avacopan-amnog-resolution-advocate-week26-no-added-benefit-2026-03-05 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/hta-organizational-impact-france-australia-evidence-readiness-playbook-2026-03-13 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/smc-seladelpar-livdelzi-resubmission-non-recommendation-pbc-2026-03-09 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/fda-loargys-accelerated-approval-arg1-deficiency-trial1-lineage-2026-02-23 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/cross-agency-non-submission-risk-hta-evidence-readiness-playbook-2026-03-13 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/fda-tecvayli-majestec3-combination-indication-expansion-2026-03-05 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/abangelabs-itc-studio-three-ecosystem-upgrade-executive-overview-2026-03-13 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/nice-ruxolitinib-ta1132-terminated-appraisal-no-evidence-submission-2026-02-17 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/dynamic-value-modeling-hta-long-term-uncertainty-evidence-governance-playbook-2026-03-13 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/ema-ixchiq-prac-aseptic-meningitis-product-information-update-2026-03-12 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/smc-vorasidenib-voranigo-acceptance-grade2-glioma-phase3-lineage-2026-03-09 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/anchored-itc-common-comparator-governance-playbook-2026-03-14 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/smc-isatuximab-non-submission-ndmm-autologous-transplant-2026-03-09 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/smc-submission-type-routing-evidence-readiness-playbook-2026-03-14 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/ema-xolremdi-whim-exceptional-circumstances-positive-opinion-rct-lineage-2026-03-14 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/smc-alyftrek-restricted-acceptance-cftr-modulator-active-comparator-lineage-2026-03-14 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/smc-sacituzumab-govitecan-non-submission-hr-positive-her2-negative-breast-cancer-2026-03-15 2026-03-15 monthly 0.8 https://www.mattheneus.com/editorial/smc-pembrolizumab-smc2915-non-submission-mesothelioma-2026-03-15 2026-03-15 monthly 0.8 https://www.mattheneus.com/editorial/nice-acoramidis-ta1121-recommendation-maic-comparator-bridge-2026-03-15 2026-03-15 monthly 0.8 https://www.mattheneus.com/editorial/nice-fezolinetant-vasomotor-menopause-final-draft-guidance-2026-03-11 2026-03-15 monthly 0.8 https://www.mattheneus.com/editorial/depression-outcome-measurement-heterogeneity-itc-nma-comparability-playbook-2026-03-15 2026-03-15 monthly 0.8 https://www.mattheneus.com/editorial/cvmp-novel-therapy-risk-template-3dp-quality-evidence-governance-playbook-2026-03-16 2026-03-16 monthly 0.8 https://www.mattheneus.com/editorial/ncpe-amivantamab-hta-24032-non-reimbursement-egfr-exon20ins-2026-03-16 2026-03-16 monthly 0.8 https://www.mattheneus.com/editorial/model-based-nma-treatment-duration-governance-playbook-2026-03-16 2026-03-16 monthly 0.8 https://www.mattheneus.com/editorial/mhra-ziihera-zanidatamab-her2-btc-irp-approval-single-arm-2026-02-19 2026-03-16 monthly 0.8 https://www.mattheneus.com/editorial/cross-domain-nma-transitivity-stress-testing-playbook-2026-03-16 2026-03-16 monthly 0.8 https://www.mattheneus.com/editorial/zin-voxzogo-netherlands-no-reimbursement-filing-access-block-2026-03-13 2026-03-17 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-cemiplimab-cscc-adjuvant-no-added-benefit-c-post-follow-up-2026-03-16 2026-03-17 monthly 0.8 https://www.mattheneus.com/editorial/nice-ruxolitinib-cream-ta1140-final-guidance-non-segmental-vitiligo-2026-03-17 2026-03-17 monthly 0.8 https://www.mattheneus.com/editorial/access-generic-medicines-work-sharing-evidence-governance-playbook-2026-03-17 2026-03-17 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-iptacopan-a25-157-c3-glomerulopathy-added-benefit-not-proven-2026-03-16 2026-03-17 monthly 0.8 https://www.mattheneus.com/editorial/mhra-nice-aligned-pathway-integrated-scientific-advice-launch-2026-03-17 2026-03-17 monthly 0.8 https://www.mattheneus.com/editorial/cochrane-ai-synthesis-march2026 2026-03-11 monthly 0.8 https://www.mattheneus.com/editorial/fda-hernexeos-her2-mutant-nsclc-efficacy-supplement-beamion-lung1-2026-02-26 2026-03-18 monthly 0.8 https://www.mattheneus.com/editorial/nice-ta1141-nivolumab-chemotherapy-urothelial-cancer-terminated-appraisal-2026-03-17 2026-03-18 monthly 0.8 https://www.mattheneus.com/editorial/ema-prime-three-feature-evidence-readiness-playbook-2026-03-18 2026-03-18 monthly 0.8 https://www.mattheneus.com/editorial/fda-dupixent-afrs-efficacy-supplement-aims-nct04684524-2026-02-23 2026-03-19 monthly 0.8 https://www.mattheneus.com/editorial/fda-icotyde-icotrokinra-plaque-psoriasis-approval-pso-program-2026-03-17 2026-03-21 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-mirdametinib-ezmekly-nf1-non-quantifiable-added-benefit-reneu-2026-03-19 2026-03-21 monthly 0.8 https://www.mattheneus.com/editorial/ema-onerji-positive-opinion-advanced-parkinsons-infusion-lineage-2026-02-26 2026-03-21 monthly 0.8 https://www.mattheneus.com/editorial/fatigue-nma-outcome-construct-governance-evidence-readiness-playbook-2026-03-20 2026-03-20 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-trastuzumab-deruxtecan-a25-128-hint-considerable-added-benefit-destiny-gastric04-2026-03-19 2026-03-20 monthly 0.8 https://www.mattheneus.com/editorial/mhra-vape-regulator-profile-evidence-governance-playbook-2026-03-20 2026-03-20 monthly 0.8 https://www.mattheneus.com/editorial/mhra-clinical-trials-regulations-enforcement-helsinki-alignment-guidance-2026-03-19 2026-03-20 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-asciminib-a25-150-first-line-minor-added-benefit-hint-second-line-not-proven-2026-02-26 2026-03-20 monthly 0.8 https://www.mattheneus.com/editorial/nice-hybrid-closed-loop-rollout-evidence-telemetry-playbook-2026-03-20 2026-03-20 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-nirmatrelvir-ritonavir-pediatric-covid19-added-benefit-not-proven-2026-03-16 2026-03-19 monthly 0.8 https://www.mattheneus.com/editorial/mhra-onkotrone-class-4-defect-notification-contraception-duration-pil-update-2026-03-17 2026-03-21 monthly 0.8 https://www.mattheneus.com/editorial/ncpe-pembrolizumab-hta24013-perioperative-nsclc-cost-effectiveness-gap-2026-03-10 2026-03-21 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-lisocabtagene-maraleucel-mcl-added-benefit-not-proven-unanchored-maic-2026-03-16 2026-03-21 monthly 0.8 https://www.mattheneus.com/editorial/fda-desmoda-nda219873-central-diabetes-insipidus-new-dosage-form-approval-2026-02-25 2026-03-19 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-linvoseltamab-amnog-resolution-no-added-benefit-linker-mm1-2026-03-19 2026-03-19 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-pirtobrutinib-mcl-prescribing-authority-restriction-consultation-evidence-gap-2026-02-24 2026-03-19 monthly 0.8 https://www.mattheneus.com/editorial/pbac-glp1-equitable-access-managed-rollout-evidence-governance-playbook-2026-03-22 2026-03-22 monthly 0.8 https://www.mattheneus.com/editorial/ema-management-board-governance-stack-evidence-operations-playbook-2026-03-19 2026-03-19 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-beremagene-geperpavec-deb-non-quantifiable-added-benefit-gem3-2026-02-19 2026-03-19 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-nivolumab-a25-154-adjuvant-urothelial-carcinoma-sex-specific-added-benefit-2026-03-16 2026-03-22 monthly 0.8 https://www.mattheneus.com/editorial/pbac-dusc-utilisation-refresh-resubmission-evidence-feedback-loop-playbook-2026-03-22 2026-03-22 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-march-2026-closure-wave-comparator-governance-evidence-playbook-2026-03-22 2026-03-22 monthly 0.8 https://www.mattheneus.com/editorial/pbac-first-time-non-recommendation-deferral-intelligence-market-access-playbook-2026-03-22 2026-03-22 monthly 0.8 https://www.mattheneus.com/editorial/genomic-hta-methodological-bottlenecks-living-evidence-playbook-2026-03-23 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/mhra-clinical-trial-record-archiving-retention-guidance-transition-31a-2026-03-19 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/fda-sotyktu-psoriatic-arthritis-efficacy-supplement-acr20-lineage-2026-03-06 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/mhra-improving-patient-information-digital-leaflet-governance-playbook-2026-03-23 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/hta-transportability-iosw-cross-country-evidence-transfer-playbook-2026-03-23 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-tislelizumab-es-sclc-first-line-no-added-benefit-rationale312-2026-03-19 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/fda-loargys-arg1-deficiency-approval-trial1-lineage-accelerated-pathway-2026-03-23 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/adaptive-trial-to-economic-model-lineage-hta-evidence-governance-playbook-2026-03-23 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/fda-approval-mix-labeling-rems-supplement-wave-evidence-governance-playbook-2026-03-24 2026-03-24 monthly 0.8 https://www.mattheneus.com/editorial/nma-reporting-rigor-top-medical-journals-transitivity-governance-playbook-2026-03-24 2026-03-24 monthly 0.8 https://www.mattheneus.com/editorial/pbac-july-2026-agenda-consultation-window-evidence-freeze-playbook-2026-03-25 2026-03-25 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-ldct-lung-cancer-screening-statutory-health-insurance-germany-2026-03-13 2026-03-26 monthly 0.8 https://www.mattheneus.com/editorial/tlv-avapritinib-ayvakyt-limited-reimbursement-gist-systemic-mastocytosis-2026-03-24 2026-03-26 monthly 0.8 https://www.mattheneus.com/editorial/nice-htg773-ai-colonoscopy-polyp-detection-evidence-generation-period-2026-03-19 2026-03-25 monthly 0.8 https://www.mattheneus.com/editorial/nice-htg774-htg775-lv-microaxial-flow-pump-cardiogenic-shock-evidence-generation-2026-03-25 2026-03-25 monthly 0.8 https://www.mattheneus.com/editorial/fallback-canary-non-proportional-hazards-nma-tte-governance-playbook-2026-03-25 2026-03-25 monthly 0.8 https://www.mattheneus.com/editorial/tlv-new-regulations-subsidy-pricing-consultation-july-2026-03-20 2026-03-25 monthly 0.8 https://www.mattheneus.com/editorial/iqwig-iptacopan-pnh-a25-156-added-benefit-not-proven-comparator-mismatch-2026-03-12 2026-03-24 monthly 0.8 https://www.mattheneus.com/editorial/cadth-reimbursement-review-itc-nma-evidence-standards-canada-market-access-playbook-2026-03-26 2026-03-26 monthly 0.8 https://www.mattheneus.com/editorial/eu-hta-jsc-application-window-2026-evidence-strategy-playbook 2026-03-26 monthly 0.8 https://www.mattheneus.com/editorial/grade-dominant-first-order-loop-nma-certainty-evidence-cinema-2026-03-27 2026-03-27 monthly 0.8 https://www.mattheneus.com/editorial/fda-cosentyx-pediatric-hidradenitis-suppurativa-efficacy-supplement-2026-03-12 2026-03-22 monthly 0.8 https://www.mattheneus.com/editorial/fallback-canary-publication-bias-nma-comparison-adjusted-funnel-plot-playbook-2026-03-28 2026-03-28 monthly 0.8 https://www.mattheneus.com/editorial/aotmit-poland-itc-nma-eu-jca-evidence-standards-cee-market-access-playbook-2026-03-27 2026-03-27 monthly 0.8 https://www.mattheneus.com/editorial/pbs-australia-nivolumab-ipilimumab-broad-listing-advanced-cancer-2026-03-01 2026-03-26 monthly 0.8 https://www.mattheneus.com/editorial/ema-adc-regulatory-clarity-evidence-planning-2026-02-22 2026-02-22 monthly 0.8 https://www.mattheneus.com/editorial/ema-pip-psusa-weekly-cadence-evidence-maintenance-playbook-2026-03-10 2026-03-10 monthly 0.8 https://www.mattheneus.com/editorial/fallback-canary-eu-jca-amnog-30plus10day-comparator-governance-playbook-2026-03-29 2026-03-29 monthly 0.8 https://www.mattheneus.com/editorial/nma-retraction-ingestion-governance-playbook-2026-03-29 2026-03-29 monthly 0.8 https://www.mattheneus.com/editorial/ema-imdylltra-tarlatamab-positive-opinion-relapsed-es-sclc-2026-03-26 2026-03-29 monthly 0.8 https://www.mattheneus.com/editorial/australia-oncology-hta-uncertainty-managed-entry-evidence-governance-playbook-2026-03-14 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/fda-adquey-difamilast-atopic-dermatitis-approval-2026-02-12 2026-03-15 monthly 0.8 https://www.mattheneus.com/editorial/ema-adstiladrin-conditional-opinion-bcg-unresponsive-nmibc-single-arm-lineage-2026-03-26 2026-03-29 monthly 0.8 https://www.mattheneus.com/editorial/hta-consumer-panel-governance-playbook-singapore-ace-2026-03-29 2026-03-29 monthly 0.8 https://www.mattheneus.com/editorial/ema-biosimilar-tailored-clinical-approach-ces-waiver-readiness-playbook-2026-03-30 2026-03-30 monthly 0.8 https://www.mattheneus.com/editorial/hta-value-nma-projections-evidence 2026-03-18 monthly 0.8 https://www.mattheneus.com/editorial/ema-fubelv-positive-opinion-etanercept-biosimilar-evidence-lineage-2026-02-26 2026-03-13 monthly 0.8 https://www.mattheneus.com/editorial/amnog-haemophilia-split-population-evidence-architecture-inhibitor-stratification-playbook-2026-03-26 2026-03-26 monthly 0.8 https://www.mattheneus.com/editorial/gene-therapy-single-arm-hta-economic-evidence-playbook-2026-03-27 2026-03-27 monthly 0.8 https://www.mattheneus.com/editorial/mhra-supply-chain-cyber-security-evidence-operations-playbook-2026-03-01 2026-03-01 monthly 0.8 https://www.mattheneus.com/editorial/fda-sogroya-pediatric-growth-indications-efficacy-supplements-sga-ns-iss-2026-02-27 2026-03-23 monthly 0.8 https://www.mattheneus.com/editorial/nice-eq5d-5l-value-set-modular-update-cost-effectiveness-governance-playbook-2026-03-29 2026-03-29 monthly 0.8 https://www.mattheneus.com/editorial/pbac-blinatumomab-pre-b-cell-all-listing-amendment-d-alba-lineage-2026-03-14 2026-03-14 monthly 0.8 https://www.mattheneus.com/editorial/nice-ta1142-dupilumab-copd-biomarker-stratified-evidence-stopping-rule-standards-2026-03-26 2026-03-28 monthly 0.8 https://www.mattheneus.com/editorial/when-two-nmas-disagree-similarity-consistency-governance-playbook-2026-04-01 2026-04-01 monthly 0.8 https://www.mattheneus.com/editorial/ai-evidence-synthesis-validation-coverage-gap-playbook-2026-04-01 2026-04-01 monthly 0.8 https://www.mattheneus.com/editorial/rwe-submission-architecture-canada-eu-hta-evidence-planning-playbook-2026-04-01 2026-04-01 monthly 0.8 https://www.mattheneus.com/editorial/infant-toddler-utility-measurement-cost-effectiveness-governance-playbook-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-concizumab-haemophilia-a-added-benefit-not-proven-comparator-mismatch-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/ema-tecovirimat-siga-mpox-restriction-four-rcts-no-benefit-2026-03-26 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-long-post-covid-annex-vi-off-label-four-drugs-evidence-lineage-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/eastern-europe-central-asia-hta-capacity-building-governance-playbook-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/hta-submissions-comparative-evidence-economic-model-lineage-problem-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/mhra-non-animal-methods-module-4-advance-review-guidance-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/car-t-global-hta-access-lag-cost-effectiveness-playbook-2026-04-02 2026-04-02 monthly 0.8 https://www.mattheneus.com/editorial/target-trial-emulation-rwd-cost-effectiveness-hta-playbook-2026-04-03 2026-04-03 monthly 0.8 https://www.mattheneus.com/editorial/nice-semaglutide-cardiovascular-risk-final-draft-guidance-select-lineage-2026-03-25 2026-04-01 monthly 0.8 https://www.mattheneus.com/editorial/europe-precision-oncology-molecular-diagnostics-hta-readiness-playbook-2026-04-03 2026-04-03 monthly 0.8 https://www.mattheneus.com/editorial/g-ba-nirogacestat-ogsiveo-small-added-benefit-defi-lineage-2026-04-03 2026-04-03 monthly 0.8 https://www.mattheneus.com/editorial/has-joe-digital-therapy-dtx-paediatric-asthma-first-reimbursement-2026-04-02 2026-04-03 monthly 0.8 https://www.mattheneus.com/editorial/nice-pmg36-cost-effectiveness-threshold-update-march-2026 2026-04-03 monthly 0.8 https://www.mattheneus.com/editorial/ehds-year-one-secondary-use-evidence-readiness-playbook-2026-04-03 2026-04-03 monthly 0.8 https://www.mattheneus.com/editorial/ai-routine-care-data-visibility-hta-validity-governance-playbook-2026-04-04 2026-04-04 monthly 0.8 https://www.mattheneus.com/editorial/mhra-fda-uk-us-pharmaceutical-medical-device-partnership-2026-04-02 2026-04-04 monthly 0.8 https://www.mattheneus.com/editorial/ema-virtual-control-groups-nonclinical-evidence-governance-playbook-2026-04-04 2026-04-04 monthly 0.8 https://www.mattheneus.com/editorial/pbac-seladelpar-primary-biliary-cholangitis-pbs-recommendation-intracycle-2026-04-04 2026-04-04 monthly 0.8 https://www.mattheneus.com/editorial/ema-consultation-wave-als-pah-trial-design-governance-playbook-2026-04-04 2026-04-04 monthly 0.8